|
DUBLIN,
Ireland and PRAGUE, Czech Republic, May 11 /PRNewswire-FirstCall/
-- Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM: AP.L),
the healthcare technology company focussed on the consumer woundcare, oral care
and coronary health markets, today announces the signing of a technology and
product development agreement with nanofibre technology specialists ELMARCO
s.r.o. ("Elmarco") of the Czech Republic for the development of a next generation
delivery platform for Alltracel's m-doc(TM) technology.
Elmarco ( www.elmarco.cz/en_profil.php )
is a specialist R&D and manufacturing company specialising
in advanced manufacturing for the semi-conductor components
industry as well as equipment for industrial production
of nanofibrous non-woven materials.
Together
with the Textiles Faculty of the Technical University
of Liberic, Elmarco have developed a novel, proprietary & patented
process for spinning polymers into nano-scale fibres
for a range of industrial, chemical, micro-electronic
and bio-medical applications.
Over the past few months m-doc(TM) based nanofibre
woundcare prototypes have been developed and are now
at an advanced stage of technical evaluation.
Alltracel's
CEO Tony Richardson commented, "Alltracel
has always been committed to innovation in our markets
and we are particularly excited by the prospects for
m-doc(TM) based nanofibrous advanced woundcare delivery
systems.
Although at an early stage of development nanofibre
technology is showing market transforming potential
in a number of our markets and we are delighted to
have formalised our partnership with Elmarco and the
nanofibre technology team at the Technical University
of Liberic.
We
are now focussed on jointly reviewing a range of
patent protected potential applications for m-doc(TM)
based nanofibre solutions, initially for the advanced
woundcare and surgical markets and bringing these
innovations to market via our network of existing
and new commercial partners."
Notes to Editors
Alltracel (AIM: AP.L) ( www.alltracel.com )
Alltracel Pharmaceuticals Plc is a Healthcare Technology
Company focussed on the Consumer Woundcare, Oral-Care
and Coronary Health markets.
With
corporate headquarters in Dublin, Ireland; Alltracel
has a commercial office in London, England; R&D
subsidiary in the Czech Republic and manufacturing
facilities in Shenzhen, China.
Alltracel was founded in 1996 and listed on London's
Alternative Investment Market in July 2001.
m-doc(TM) (Micro Dispersed Oxidized Cellulose; ( www.m-doc.com ))
is the end product of Alltracel's patented process
and is currently targeting two major markets.
- In the Consumer HealthCare market this process applied
to cotton in the form of raw cellulose is proven as
an effective and efficient haemostatic (blood-stopping)
agent. Here m-doc(TM) is currently being marketed as
the leading stops bleeding ingredient brand within
recognized wound care, oral care and relevant first
aid brands worldwide.
- In the Coronary Health market, EU based pre-clinical
and patient studies have demonstrated the m-doc(TM)
technology platform success in lowering cholesterol
and have indicated longer term coronary health benefits.
In addition pre-clinical work showed significant indications
that the m-doc(TM) coronary health benefits are additive
in nature, to both statins and sterols. Further efficacy,
dosage and timing/phasing studies to determine optimum
delivery systems, formats and combinations in both
the nutraceutical and pharmaceutical markets are underway.
Development discussions with potential partners in
the nutraceutical and pharmaceutical sectors in both
the EU and North America have commenced.
blotters(TM) is Alltracel's branded blood stopping
thin film technology for the consumer first aid and
grooming markets. The blotters(TM) are small, thin,
film strips (similar to breath freshener strips) impregnated
with m-doc(TM) - Alltracel's unique blood stopping
ingredient and are packed in a convenient pocket-sized
plastic dispenser. When placed on minor cuts e.g. shaving
nicks m-doc(TM) is released on contact with the blood,
forming a soft gel-like layer over the wound to stop
the bleeding fast.
SEAL-ON(TM) ( www.seal-on.com )
is the world's first first-aid treatment brand featuring
stops bleeding m-doc(TM) as standard. The SEAL-ON(TM)
range features seven different product delivery systems
- sprays, nasal plugs, patches, powder, plasters, dressings
and blotters(TM) -- each designed for specific usage
occasions and all containing the stops-bleeding m-doc(TM)
ingredient brand.
m-doc(TM), blotters(TM), SEAL-ON(TM) are all trademarks
of Alltracel Pharmaceuticals Plc.
For further information contact: Dublin: Denise Cronin
Alltracel: +353-1-235-2162 press@alltracel.com London:
Deborah Scott/Davina Langdale Financial Dynamics: +44-207-831-3113
New York: Sean Leous Financial Dynamics: +1-212-850-5626
Source: Alltracel Pharmaceuticals Plc
|
